Korea FDA Mulls Detailed Biosimilar Guidelines To Boost Homegrown Firms
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Sensing big potential for the biosimilars segment, Korea FDA has embarked upon a plan to improve its guidelines on standardization and quality that can eventually enable its homegrown companies to develop a sizeable pipeline of biosimilar products. The agency intends to implement the guidelines in 2011
You may also be interested in...
With Samsung's Push For MabThera Biosimilar, Roche Persists On Call For Strengthened Regulatory Framework
SEOUL - In reaction to South Korean firm Samsung Electronics' recent clinical trial application for its biosimilar of Roche's MabThera, Roche said that it supports developing a regulatory framework for biosimilars that would apply the same stringent standards as those applied to originator products to ensure the protection of public health
With Samsung's Push For MabThera Biosimilar, Roche Persists On Call For Strengthened Regulatory Framework
SEOUL - In reaction to South Korean firm Samsung Electronics' recent clinical trial application for its biosimilar of Roche's MabThera, Roche said that it supports developing a regulatory framework for biosimilars that would apply the same stringent standards as those applied to originator products to ensure the protection of public health
South Korea To Strengthen Medical Equipment Sector
SEOUL - Ahead of the July 2011 launch of Korea-EU free trade agreement, which local observers fear could damage the local healthcare sector, the Korean government is hammering out a set of measures to help the country's medical equipment industry